Spots Global Cancer Trial Database for Efgartigimod Expanded Access for Generalized Myasthenia Gravis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efgartigimod Expanded Access for Generalized Myasthenia Gravis
Official Title: An Expanded Access Program for Efgartigimod Treatment in Patients With Generalized Myasthenia Gravis
Study ID: NCT04777734
Conditions
Interventions
Study Description
Brief Summary: This expanded access protocol applies to patients with gMG who are not enrolled in an ongoing clinical trial. The aim of the trial is to provide patients with generalized myasthenia gravis (gMG), who are ineligible to participate in a clinical trial, access to efgartigimod treatment before regulatory approval. There are country-specific protocols and also individual use EAP. Recruitment for the treatment protocol in US is now closed (ARGX-113-EAP-2101).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Investigator site 12 - Approved for Marketing, Chicago, Illinois, United States
Investigator site 16 - Approved for Marketing, Lexington, Kentucky, United States
Investigator site 1 - Approved for Marketing, Ann Arbor, Michigan, United States
Investigator Site 6 - Approved for Marketing, New Hyde Park, New York, United States
Investigator site 14 - Approved for Marketing, Philadelphia, Pennsylvania, United States
Investigator site 2 - Approved for Marketing, Henrico, Virginia, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
